Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis
Open Access
- 9 July 2022
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26680
Abstract
Coronary vessel disease (CVD) is a class of diseases that impacts the blood vessels and heart and is one of the leading causes of disability and death. CVD includes cerebrovascular disease and coronary heart disease, both illnesses of the vessels transporting the oxygenated blood to the brain or heart. Colchicine is an inexpensive and old drug with strong anti-inflammatory effects. Numerous randomized control trials (RCTs) have demonstrated the effectiveness of low-dose colchicine for the prevention of severe cardiovascular events without showing any signs of serious adverse effects within the regime of treatment. In the current meta-analysis, we aim to assess the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD. The current meta-analysis was carried out using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. PUBMED, Cochrane, and EMBASE databases were used to search for RCTs comparing colchicine and placebos for the prevention of secondary cardiovascular outcomes. The primary efficacy endpoint was mortality due to cardiovascular disease, stroke, urgent coronary revascularization, and myocardial infarction. Secondary efficacy outcomes included death due to all-cause mortality. Seven RCTs were reviewed, with a pooled sample size of 12114, out of which 6099 were randomized to the colchicine group, and 6015 were randomized to the control group. The decrease in cardiovascular events, including myocardial infarction, stroke, urgent coronary revascularization, and cardiac-related death, was significantly lower in patients randomized to colchicine (p-value0.05). In patients with CVD, compared to standard medical therapy, colchicine significantly decreases the risk of cardiovascular events such as cardiovascular-related death, myocardial infarction, stroke, and urgent coronary revascularizations.Keywords
This publication has 26 references indexed in Scilit:
- Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart FailureJACC: Heart Failure, 2014
- Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular DiseaseJournal of Cardiovascular Pharmacology and Therapeutics, 2013
- Mechanisms of Acute Coronary Syndromes and Their Implications for TherapyNew England Journal of Medicine, 2013
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular DiseaseJACC, 2013
- High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine studyArthritis & Rheumatism, 2010
- Inflammation and Plaque VulnerabilityCardiovascular Drugs and Therapy, 2008
- Effect of Colchicine (0.5 mg Twice Daily) on High-Sensitivity C-Reactive Protein Independent of Aspirin and Atorvastatin in Patients With Stable Coronary Artery DiseaseThe American Journal of Cardiology, 2007
- Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2006
- Performance of maximum parsimony and likelihood phylogenetics when evolution is heterogeneousNature, 2004
- Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplastyJACC, 1992